Агренокс и вторичная профилактика ишемических инсультов

1. Стаховская Л.В., Мешкова К.С., Шеховцова К.В., Скворцова В.И.  Дифференцированная вторичная профилактика инсульта: дополнение к рекомендациям. Consilium Medicum. Неврология 2009; 1: 16–8.
2. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 1996; 348: 1329–39.
3. Adams RJ, Albers G, Alberts MJ et al. Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke 2008; 39(5): 1647–52.
4. Adams RJ. Secondary Prevention of Atherothrombotic Events After Ischemic Stroke. Mayo Clin Proc 2009; 84(1): 43–51.
5. Albers GW, Amarenco P, Easton JD et al. Antithrombotic and thrombolytic therapy for ischemic stroke: the Seventh ACCP Conference on Antithrombotic and Thombolytic Therapy. Chest 2004; 126(3; suppl): 483S–512.
6. Algra A, van Gijn. Cumulative meta-analysis of aspirin efficacy after cerebral ischaemia of arterial origin. J Neurol Neurosurg Psychiatry 1999; 66: 255.
7. Anderson JL, Adams CD, Antman EM et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non–ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2008; 117(9): e180. 
8. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71–86.
9. Barnett HJ, Eliasziw M, Meldrum H. Drugs and surgery in the prevention of ischemic stroke. N Engl J Med 1995; 332: 238–48. 
10. Bhatt DL, Steg PG, Ohman EM et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006; 295: 180–9.
11. CAPRIE Steering Committee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 1996; 348: 1329–39.
12. Chimowitz MI, Lynn MJ, Howlett-Smith H et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 2005; 352: 1305–16.
13. Coull AJ, Lovett JK, Rothwell PM. Population based study of early risk of stroke after transient ischaemic attack or minor stroke: implications for public education and organisation of services. BMJ 2004; 328: 326. 
14. Coutts SB, Hill MD, Campos CR et al. Recurrent Events in Transient Ischemic Attack and Minor Stroke. What Events Are Happening and to Which Patients? Stroke 2008; 39: 2461–6.
15. Dennis MS, Bamford JM, Sandercock PAG, Warlow CP. A comparison of risk factors and prognosis for transient ischemic attacks and minor ischemic strokes. Stroke 1989; 20: 1494–9.
16. Diener HC, Cunha L, Forbes C et al. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143: 1–13.
17. Diener HC, Bogousslavsky J, Brass LM et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004; 364: 331–7.
18. Diener HC, Sacco R, Yusuf S. Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS). Cerebrovasc Dis 2007; 23: 368–80.
19. Diener HC, Sacco RL, Yusuf S et al. Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study. Lancet. Neurology 2008; 8: 1–10.
20. Dhamoon MS, Sciacca RR, Rundek T et al. Recurrent stroke and cardiac risks after first ischemic stroke: the Northern Manhattan Study. Neurology 2006; 66: 641–6.
21. Dutch TIA Trial Study Group.  A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 1991; 325(18): 1261–6.
22. Eliasziw M, Kennedy J, Hill MD et al. North Am Symptomatic Carotid Endarterectomy Trial Group. Early risk of stroke after a transient ischemic attack in patients with internal carotid artery disease. CMAJ 2004; 170: 1105–9.
23. European Stroke Organization (ESO) Executive Committee, ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 2008; 25: 457–507.
24. Friedman GD, Wilson WS, Mosier JM et al. Transient ischemic attacks in a community. JAMA 1969; 210: 1428–34.
25. Gent M, Blakely JA, Easton JD et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989; 1: 1215–20.
26. Goldstein LB, Adams R, Alberts MJ et al. Primary prevention of ischemic stroke: a guideline fr om the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 2006; 114(22): e617.
27. Hass WK, Easton JD, Adams HP et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989; 321: 501–7.
28. Hill MD, Yiannakoulias N, Jeerakathil T et al. The high risk of stroke immediately after transient ischemic attack: a population-based study. Neurology 2004; 62: 2015–20.
29. Johnson ES, Lanes SF, Wentworth CE III et al. A metaregression analysis of the dose-response effect of aspirin on stroke. Arch Intern Med 1999; 159: 1248–53.
30. Johnston SC, Gress DR, Browner WS, Sidney S. Short-term prognosis after emergency department diagnosis of TIA. JAMA 2000; 284: 2901–6.
31. Mohr JP, Thompson JLP, Lazar RM et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001; 345: 1444–51.
32. Sacco RL, Adams R, Albers G et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke. Co-sponsored by the Council on Cardiovascular Radiology and Intervention. The American Academy of Neurology affirms the value of this guideline. Stroke 2006; 37: 577–617.
33. Sacco RL, Diener HC, Yusuf S et al. PRoFESS Study Group. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med. 2008; 359(12): 1238–51.
34. SALT Collaborative Group. Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet 1991; 338(8779): 1345–9.
35. Sze PC, Reitman D, Pincus MM et al. Antiplatelet agents in the secondary prevention of stroke: meta-analysis of the randomized control trials. Stroke 1988; 19(4): 436–42.
36. Talelli P, Greenwood RJ. Review: Recurrent stroke: wh ere do we stand with the secondary prevention of noncardioembolic ischaemic strokes? Therapeutic Advances in Cardiovascular Disease 2008; 2(5): 387–405.
37. The ESPRIT Study Group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006; 367: 1665–73.
38. The ESPRIT Study Group. Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial. Lancet. Neurol 2007; 6: 115–24.
39. Thom T, Haase N, Rosamond W et al. Heart disease and stroke statistics to 2006 update. A report from the American Heart Association Statistics Committee and the Stroke Statistics Subcommittee. Circulation 2006; 113: e85–151.
40. Verro P, Gorelick PB, Nguyen D. Aspirin Plus Dipyridamole Versus Aspirin for Prevention of Vascular Events After Stroke or TIA. A Meta-Analysis. Stroke 2008; 39: 1358–63.
41. Whisnant JP, Matsumoto N, Elveback LR. Transient cerebral ischemic attacks in a community. Mayo Clin Proc 1973; 48: 194–8.